These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38483962)

  • 21. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
    Scahill L; Chappell PB; Kim YS; Schultz RT; Katsovich L; Shepherd E; Arnsten AF; Cohen DJ; Leckman JF
    Am J Psychiatry; 2001 Jul; 158(7):1067-74. PubMed ID: 11431228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis.
    Ruggiero S; Clavenna A; Reale L; Capuano A; Rossi F; Bonati M
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1578-90. PubMed ID: 25156577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; McBurnett K; White C; Youcha S
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
    Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
    Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
    Newcorn JH; Harpin V; Huss M; Lyne A; Sikirica V; Johnson M; Ramos-Quiroga JA; van Stralen J; Dutray B; Sreckovic S; Bloomfield R; Robertson B
    J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience.
    Chappell PB; Riddle MA; Scahill L; Lynch KA; Schultz R; Arnsten A; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1140-6. PubMed ID: 7559307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder.
    Rostain AL
    Curr Psychiatry Rep; 2009 Oct; 11(5):339-40. PubMed ID: 19785972
    [No Abstract]   [Full Text] [Related]  

  • 30. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Kosheleff AR; Hull JT; Liranso T; Qin P; Busse GD; O'Neal W; Fava M; Faraone SV; Rubin J
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):214-226. PubMed ID: 33600233
    [No Abstract]   [Full Text] [Related]  

  • 31. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
    Scahill L; McCracken JT; King BH; Rockhill C; Shah B; Politte L; Sanders R; Minjarez M; Cowen J; Mullett J; Page C; Ward D; Deng Y; Loo S; Dziura J; McDougle CJ;
    Am J Psychiatry; 2015 Dec; 172(12):1197-206. PubMed ID: 26315981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G; Arnold V; Yan B; Yu M; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
    [No Abstract]   [Full Text] [Related]  

  • 33. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
    Michelini G; Lenartowicz A; Vera JD; Bilder RM; McGough JJ; McCracken JT; Loo SK
    J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):415-426. PubMed ID: 35963559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM; Greenhill LL; Lopez FA; Sedillo A; Earl CQ; Jiang JG; Biederman J
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder.
    Newcorn JH; Huss M; Connor DF; Hervás A; Werner-Kiechle T; Robertson B
    J Dev Behav Pediatr; 2020 Sep; 41(7):565-570. PubMed ID: 32482970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
    Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
    J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study.
    Naya N; Sakai C; Okutsu D; Kiguchi R; Fujiwara M; Tsuji T; Iwanami A
    Neuropsychopharmacol Rep; 2021 Mar; 41(1):26-39. PubMed ID: 33305542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis.
    Yu S; Shen S; Tao M
    J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):40-50. PubMed ID: 36944092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.